Clinical Trial Update: A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety, tolerability, and efficacy of Certican in de novo heart transplantation patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Transplantation

Drugs mentioned

• Certican (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Heart Transplantation | Phase 3 | Status: COMPLETED